Pharma BD Deal Intelligence
Amgen's $2.8B strategic collaboration handed BeiGene commercialization rights to 20 oncology products across China—including Xgeva, Kyprolis, Blincyto, and sotorasib—for a 20.5% equity stake, giving Amgen instant China market access without building local infrastructure from scratch.
Amgen's China ambitions become clear with the BeiGene deal, committing $2.7 billion for a 20.5% stake and collaboration to advance 20 oncology medicines in the…
Amgen and BeiGene collaborate to advance 20 oncology medicines in China including XGEVA KYPROLIS BLINCYTO and AMG 510 sotorasib with shared development costs.
BeiGene, Ltd. — the BeiGene counterparty to Amgens 2020 strategic collaboration — announced its new name, BeOne Medicines Ltd., and redomiciliation from the…
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
Amgen entered a strategic collaboration with BeiGene to expand its oncology presence in China, investing $2.7B for a 20.5% equity stake with BeiGene commercializing 20 Amgen oncology products in China.
Lumakras (sotorasib) faces a rapidly crowding KRAS G12C and adjacent-target landscape in 2L+ NSCLC. Covalent KRAS G12C inhibitors: Lumakras received FDA accelerated approval (2021), with full approval maintained in 2L KRAS G12C-mutant NSCLC after CodeBreaK 200; Amgen guided 2023 Lumakras sales of roughly $200M, below early expectations. Krazati (adagrasib, Bristol-Myers Squibb via Mirati acquisition) is the direct comparator, FDA accelerated approval 2022 in 2L KRAS G12C NSCLC with KRYSTAL-1 data and Phase 3 KRYSTAL-12 readout favoring adagrasib versus docetaxel. Divarasib (GDC-6036, Roche/Genentech) and opnurasib (JDQ443, Novartis) are Phase 2/3 next-gen G12C inhibitors with improved selectivity profiles. Pan-KRAS/pan-RAS inhibitors: Revolution Medicines' RMC-6236 (daraxonrasib, pan-RAS(ON)) and RMC-6291 (G12C(ON)) in Phase 3 threaten to leapfrog covalent inhibitors via broader mutation coverage and better CNS penetration. SHP2/SOS1 combination partners: noncompetitive directly but expected to stack with G12C. Standard-of-care backbone: Keytruda (pembrolizumab, Merck) +/- platinum chemotherapy remains 1L standard for PD-L1-stratified populations (~$25B franchise), constraining G12C drugs to 2L until frontline combo data mature. Commercial threat is Krazati displacement and the Revolution Medicines pan-RAS pipeline compressing the covalent G12C window.
Kyprolis (carfilzomib) is positioned as the second-generation proteasome inhibitor but faces compressing share across five MOA classes in multiple myeloma. Proteasome inhibitors: Velcade (bortezomib, Takeda/J&J) and its generics dominate frontline use after 2022 loss of exclusivity; Ninlaro (ixazomib, Takeda) is the oral alternative. Anti-CD38 monoclonal antibodies: Darzalex/Darzalex Faspro (daratumumab, J&J) generated roughly $10B in 2023 and is the dominant backbone in frontline and relapsed settings; Sarclisa (isatuximab, Sanofi) competes in relapsed/refractory. Immunomodulators: Revlimid (lenalidomide, BMS) generics launched 2022 and Pomalyst (pomalidomide, BMS) remain foundational partners. BCMA bispecifics/CAR-T: Tecvayli (teclistamab, J&J), Elrexfio (elranatamab, Pfizer), Abecma (idecabtagene vicleucel, BMS/2seventy), and Carvykti (ciltacabtagene autoleucel, J&J/Legend) have established late-line dominance, with Carvykti moving into earlier lines per CARTITUDE-4. GPRC5D bispecifics: Talvey (talquetamab, J&J) is approved in triple-class-exposed patients. Amgen reported Kyprolis 2023 global sales of roughly $1.4B, slipping as Darzalex-based quadruplets displace PI-heavy regimens. Commercial threat is highest from daratumumab-anchored combinations and BCMA/GPRC5D redirectors collapsing the addressable population for next-wave PI therapy.
Blincyto (blinatumomab) competes across three MOA classes in relapsed/refractory and MRD+ B-ALL. CD19-directed bispecific T-cell engagers: Blincyto is the only approved BiTE and now has an FDA label for MRD+ and newly diagnosed Ph-negative B-ALL after the E1910 Phase 3 readout (NEJM 2024), generating roughly $1.1B in 2023 Amgen product sales. CD22-directed antibody-drug conjugates: Besponsa (inotuzumab ozogamicin, Pfizer) is approved for R/R B-ALL and competes directly in adult salvage settings with competitive CR rates versus chemotherapy. CD19-directed autologous CAR-T: Kymriah (tisagenlecleucel, Novartis) is approved for pediatric/young-adult R/R B-ALL up to age 25 and Tecartus (brexucabtagene autoleucel, Kite/Gilead) is approved for adult R/R B-ALL; both deliver durable remissions but are constrained by manufacturing, REMS, and cost. Multi-tyrosine kinase inhibitors (Ph+ B-ALL only): Iclusig (ponatinib, Takeda) received full approval in frontline Ph+ B-ALL with chemo in 2024, while Sprycel (dasatinib, BMS) remains a chemo-free partner for blinatumomab per ECOG-ACRIN data. Commercial threat is highest in adult Ph-negative frontline consolidation where Blincyto has widened indications, while CAR-T dominates heavily pretreated disease and Besponsa erodes share in chemo-ineligible salvage.
Xgeva (denosumab) dominates the skeletal-related events (SRE) market in solid tumor bone metastases but competes across two established MOA classes. Anti-RANKL monoclonal antibodies: Xgeva is the sole approved agent in class, with Amgen reporting worldwide Prolia/Xgeva franchise sales exceeding $6B annually; biosimilar denosumab (Sandoz Jubbonti/Wyost, Celltrion Stoboclo/Osenvelt) launched in the US in 2025 after Amgen composition-of-matter patent expiry, compressing ASP and accelerating share loss. Bisphosphonates: Zometa (zoledronic acid, Novartis) remains the long-established IV standard of care via monthly infusion with deep generic penetration (generic zoledronic acid widely available), and Aredia (pamidronate) generics persist for patients requiring bisphosphonate backbone. Head-to-head data from Fizazi et al. Lancet 2011 established Xgeva's superiority over zoledronic acid in delaying time-to-first SRE in castration-resistant prostate cancer, solid tumors, and multiple myeloma, anchoring guideline preference. Commercial threat is now dominated by denosumab biosimilar erosion rather than cross-class switching: formularies increasingly require bisphosphonate trial or biosimilar denosumab, and renal-impaired populations favor denosumab over zoledronic acid due to nephrotoxicity risk. The branded Xgeva franchise is in managed decline.
Amgen invested $2.7B for 20.5% BeiGene stake. BeiGene to commercialize 20 Amgen oncology products in China.
BeiGene commercializing Xgeva, Kyprolis, Blincyto in China. Some products reverted to Amgen per schedule.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Amgen Inc. / BeiGene Ltd. (this deal) | 2020 | $2.8B | 68 |
| Amgen Inc. / Immunex Corporation | 2002 | $16.0B | 92 |
| Amgen Inc. / Immunex Corporation | 2001 | $16.0B | 91 |
| Amgen Inc. / Micromet Inc. | 2012 | $1.2B | 88 |
| Amgen Inc. / Five Prime Therapeutics | 2021 | $1.9B | 78 |
| Amgen Inc. / Horizon Therapeutics plc | 2022 | $27.8B | 72 |
| Amgen Inc. / Otezla (from Celgene/BMS) | 2019 | $13.4B | 68 |
← Browse all deals · How we score deals
More: 2020 deals · Amgen Inc. deals · Oncology deals